IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT :	Zhou, Ming-Ming et al.		
SERIAL NO. :	09/784,553	EXAMINER :	Not Yet Assigned
FILED :	February 16, 2001	ART UNIT :	Not Yet Assigned
FOR :	METHODS OF IDENTIFYING MODULATORS OF BROMODOMAINS		

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on April 7, 2003.

Anne M. Jones
(Name of Person Depositing Mail)

Anne M. Jones 4/7/03.
(Signature and Date)

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

Please enter the following amendments into the present application.

IN THE DRAWINGS:

Please delete Figure 13-1 through 13-13 without prejudice or disclaimer.

IN THE SPECIFICATION:

Please substitute the following amended paragraph for the paragraph on page 10, lines 19-25:

In a preferred embodiment the compound is selected by performing rational drug design with the set of atomic coordinates obtained from one or more of Tables 1-5 and 10-14. More preferably the selection is performed in conjunction with computer modeling. Compounds selected by these methods are also part of the present invention. Preferably the compound is a small organic molecule. More preferably the compound is an analog of acetyl-lysine. Even more preferably, the compound is not included in Table 15-1 to 15-33.

Please substitute the following amended paragraph for the paragraph starting on page 10, line 25 and ending on page 11, line 19:

The present invention also provides methods of identifying a compound that modulates the stability of the binding complex formed between P/CAF and Tat that is acetylated at the lysine residue at position 50 of SEQ ID NO:45. In one such embodiment the method comprises contacting the bromodomain of P/CAF or a fragment thereof with a binding partner in the presence of the compound under conditions in which the bromodomain of P/CAF and the binding partner bind in the absence of the compound. The stability of the bromodomain of P/CAF and the binding partner is then determined (*e.g.*, measured). When there is a change in the stability of the binding complex between the bromodomain of P/CAF and the binding partner in the presence of the compound, the compound is identified as a modulator. In one embodiment of this type the binding partner is Tat that is acetylated at the lysine residue at position 50 of SEQ ID NO:45. In a preferred embodiment the binding partner is a fragment of Tat comprising an acetyl-lysine at position 50. In still another embodiment the binding partner is an analog of the fragment of Tat comprising an acetyl-lysine at position 50. When the stability of the bromodomain of P/CAF for the binding partner increases in the presence of the compound, the compound is identified as a stabilizing agent, whereas when the stability of the bromodomain of P/CAF for the binding partner decreases in the presence of the compound, the compound is identified as an inhibitor of the Tat-P/CAF complex. In a preferred embodiment the compound is selected by performing rational drug design with the set of atomic coordinates obtained from one or more of Tables 1-5 and 10-14. More preferably the selection is performed in conjunction with computer modeling. Compounds identified by these methods are also part of the present invention. Preferably the compound is an analog of acetyl-lysine. More preferably the compound is a small organic molecule not included in Table 15-1 to 15-33.

Please substitute the following amended paragraph for the paragraph starting on page 11, line 27 and ending on page 12, line 2:

Another aspect of the present invention provides methods of preventing, and/or retarding the progression and/or treating HIV infection in an individual. One such method employs administering to the individual compounds that modulate the Tat-P/CAF complex selected by performing rational drug design with the set of atomic coordinates obtained from one or more of Tables 1-5 and 10-14. In a preferred embodiment the compound administered is an acetyl-lysine

analog. In a particular embodiment this compound is a small organic molecule contained in Table 15-1 to 15-33. Preferably the compound either de-stabilizes or inhibits the Tat-P/CAF complex.

Please substitute the following amended paragraph for the paragraph on page 16, line 19 through line 24:

Figure 12 depicts the chemical structure common to the acetyl-lysine analogs of the present invention. R_1, R_2, and R_3 can be H, CH_3, a halogen (*e.g.*, F, Cl, Br, I etc.), OH, SH, or NH_3^+. R4 can be an alkyl (including a peptide/protein attached thereto such as a peptide comprising an acetyl-lysine in which the "N" of the structure depicted is the epsilon nitrogen (*i.e.*, $N^{\epsilon)}$ of a lysyl residue), or an aryl group. *See also* Table 15-1 to 15-33 for examples.

Please delete line 26 on page 16.

Please substitute the following amended paragraph for the paragraph on page 20, line 11 through line 25:

The present invention provides the first detailed structural information regarding a bromodomain and a bromodomain complexed with its acetylated binding partner. The present invention therefore provides the three-dimensional structure of the bromodomain and a bromodomain acetylated binding partner complex. Since the interaction of the bromodomain with a histone for example, can play a significant role in chromatin remodeling/regulation, the structural information provided herein can be employed in methods of identifying drugs that can modulate basic cell processes by modulating the transcription. In a particular embodiment, the three-dimensional structural information is used in the design of a small organic molecule for the treatment of cancer or as disclosed below, HIV-1 infection and/or AIDs. In addition, the present invention provides a critical structural feature for a class of inhibitors (acetyl-lysine analogs) of the interaction between bromodomains and their protein binding partners which contain an acetylated-lysine (*e.g.*, Tat with P/CAF), *see* Figure 12, as well as a compilation of compounds that share this critical feature, *see* Table 15-1 to 15-33.

Please substitute the following amended paragraph for the paragraph on page 24, line 25 through line 28:

As used herein the term "acetyl-lysine analog" is used interchangeably with the term "analog of acetyl-lysine" and is a compound that contains the acetyl-amine-like structure as depicted in Figure 12. Examples of acetyl-lysine analogs are included in Table 15-1 to 15-33.

Please substitute the following amended paragraph for the paragraph on page 44, line 11 through line 17:

Initially a potential drug could be obtained by screening a random peptide library produced by recombinant bacteriophage for example, [Scott and Smith, *Science,* **249:**386-390 (1990); Cwirla *et al., Proc. Natl. Acad. Sci.,* **87:**6378-6382 (1990); Devlin *et al., Science,* **249:**404-406 (1990)] or a chemical library. In particular, based on the NMR structural analysis provided herein, compounds that comprise an "acetyl-amine-like" structure as depicted in Figure 12 are particularly good candidates. Examples of such "acetyl-lysine analogs" are included in Table 15-1 to 15-33.

Please substitute the following amended paragraph for the paragraph starting on page 55, line 28, through line 4 on page 56:

According to the invention, the component or components of a therapeutic composition, *e.g.,* an agent of the invention that interferes with the bromodomain-acetyl-lysine binding complex such as the peptide having the amino acid sequence of SEQ ID NOs:4, 5, 6, 46, or 47, or an acetyl-lysine analog as defined by Figure 12 and exemplified in Table 15-1 to 15-33, and a pharmaceutically acceptable carrier, may be introduced parenterally, transmucosally, *e.g.*, orally, nasally, or rectally, or transdermally. Preferably, administration is parenteral, *e.g.*, via intravenous injection, and also including, but is not limited to, intra-arteriole, intramuscular, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration.

Please insert Table 15-1 to 15-33, attached hereto as Table 15-1 through 15-33, into the specification after page 83 and before the claims.

IN THE CLAIMS:

Please cancel claims 37 through 43 without prejudice or disclaimer.

Please substitute the following amended claims for the original claims having the same claim number:

29. (Amended) A compound that is a small organic molecule identified by the method of Claim 28; wherein said compound is an analog of acetyl-lysine, but with the proviso that the compound is not included in Table 15-1 to 15-33.

34. (Amended) A compound that is a small organic molecule identified by the method of Claim 33; wherein said compound is an analog of acetyl-lysine, but with the proviso that the compound is not included in Table 15-1 to 15-33.

35. (Amended) An agent that can modulate the binding of P/CAF and Tat; wherein said agent is an analog of acetyl-lysine, but with the proviso that the agent is not included in Table 15-1 to 15-33.

REMARKS

Claims 1-43 are pending. Claims 37-43 have been cancelled without prejudice or disclaimer. Claims 29, 34 and 35 have been amended. Thus, claims 1-36 remain under consideration.

The amendments to the specification and claims were rendered to clarify aspects of the invention. Table 15-1 to 15-33 presents identical data to that originally included in Figure 13, which has now, accordingly, been deleted. No New Matter has been added by way of these amendments.

A Petition for Correction of Inventorship is attached herein in accordance with 1.48(b). This correction is respectfully requested in light of the claims cancelled by way of this amendment.

Attached hereto is a marked-up version of the changes made to the specification and the claims by the current amendment. The attachment is captioned "Version with markings to show changes made."

Conclusion

Examination on the merits is respectfully requested.

Respectfully submitted,

Veronica Mallon, Ph.D.
Agent for Applicants
Registration No. 52,491

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601

Date: April 7, 2003

Attachment: Table 15-1 to 15-33
Petition for Correction of Inventorship

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The following amended paragraph will replace the original paragraph on page 10, lines 19-25:

In a preferred embodiment the compound is selected by performing rational drug design with the set of atomic coordinates obtained from one or more of Tables 1-5 and 10-14. More preferably the selection is performed in conjunction with computer modeling. Compounds selected by these methods are also part of the present invention. Preferably the compound is a small organic molecule. More preferably the compound is an analog of acetyl-lysine. Even more preferably, the compound is not included in [Figure 13] Table 15-1 to 15-33.

The following amended paragraph will replace the original paragraph starting on page 10, line 25 and ending on page 11, line 19:

The present invention also provides methods of identifying a compound that modulates the stability of the binding complex formed between P/CAF and Tat that is acetylated at the lysine residue at position 50 of SEQ ID NO:45. In one such embodiment the method comprises contacting the bromodomain of P/CAF or a fragment thereof with a binding partner in the presence of the compound under conditions in which the bromodomain of P/CAF and the binding partner bind in the absence of the compound. The stability of the bromodomain of P/CAF and the binding partner is then determined (*e.g.*, measured). When there is a change in the stability of the binding complex between the bromodomain of P/CAF and the binding partner in the presence of the compound, the compound is identified as a modulator. In one embodiment of this type the binding partner is Tat that is acetylated at the lysine residue at position 50 of SEQ ID NO:45. In a preferred embodiment the binding partner is a fragment of Tat comprising an acetyl-lysine at position 50. In still another embodiment the binding partner is an analog of the fragment of Tat comprising an acetyl-lysine at position 50. When the stability of the bromodomain of P/CAF for the binding partner increases in the presence of the compound, the compound is identified as a stabilizing agent, whereas when the stability of the bromodomain of P/CAF for the binding partner decreases in the presence of the compound, the compound is identified as an inhibitor of the Tat-P/CAF complex. In a preferred embodiment the compound

is selected by performing rational drug design with the set of atomic coordinates obtained from one or more of Tables 1-5 and 10-14. More preferably the selection is performed in conjunction with computer modeling. Compounds identified by these methods are also part of the present invention. Preferably the compound is an analog of acetyl-lysine. More preferably the compound is a small organic molecule not included in [Figure 13] Table 15-1 to 15-33.

The following amended paragraph will replace the original paragraph starting on page 11, line 27 and ending on page 12, line 2:

Another aspect of the present invention provides methods of preventing, and/or retarding the progression and/or treating HIV infection in an individual. One such method employs administering to the individual compounds that modulate the Tat-P/CAF complex selected by performing rational drug design with the set of atomic coordinates obtained from one or more of Tables 1-5 and 10-14. In a preferred embodiment the compound administered is an acetyl-lysine analog. In a particular embodiment this compound is a small organic molecule contained in [Figure 13] Table 15-1 to 15-33. Preferably the compound either de-stabilizes or inhibits the Tat-P/CAF complex.

The following amended paragraph will replace the original paragraph on page 16, line 19 through line 24:

Figure 12 depicts the chemical structure common to the acetyl-lysine analogs of the present invention. R_1, R_2, and R_3 can be H, CH_3, a halogen (*e.g.*, F, Cl, Br, I etc.), OH, SH, or NH_3^+. R4 can be an alkyl (including a peptide/protein attached thereto such as a peptide comprising an acetyl-lysine in which the "N" of the structure depicted is the epsilon nitrogen (*i.e.*, $N^{\epsilon)}$ of a lysyl residue), or an aryl group. *See also* [Figure 13] Table 15-1 to 15-33 for examples.

Line 26 on page 16 has been deleted:

[Figure 13 depicts examples of acetyl-lysine analogs. **[PRIOR ART]]**

The following amended paragraph will replace the original paragraph on page 20, line 11 through line 25:

The present invention provides the first detailed structural information regarding a bromodomain and a bromodomain complexed with its acetylated binding partner. The present

invention therefore provides the three-dimensional structure of the bromodomain and a bromodomain acetylated binding partner complex. Since the interaction of the bromodomain with a histone for example, can play a significant role in chromatin remodeling/regulation, the structural information provided herein can be employed in methods of identifying drugs that can modulate basic cell processes by modulating the transcription. In a particular embodiment, the three-dimensional structural information is used in the design of a small organic molecule for the treatment of cancer or as disclosed below, HIV-1 infection and/or AIDs. In addition, the present invention provides a critical structural feature for a class of inhibitors (acetyl-lysine analogs) of the interaction between bromodomains and their protein binding partners which contain an acetylated-lysine (*e.g.*, Tat with P/CAF), *see* Figure 12, as well as a compilation of compounds that share this critical feature, *see* [Figure 13] Table 15-1 to 15-33.

The following amended paragraph will replace the original paragraph on page 24, line 25 through line 28:

As used herein the term "acetyl-lysine analog" is used interchangeably with the term "analog of acetyl-lysine" and is a compound that contains the acetyl-amine-like structure as depicted in Figure 12. Examples of acetyl-lysine analogs are included in [Figure 13] Table 15-1 to 15-33.

The following amended paragraph will replace the original the paragraph on page 44, line 11 through line 17:

Initially a potential drug could be obtained by screening a random peptide library produced by recombinant bacteriophage for example, [Scott and Smith, *Science,* **249:**386-390 (1990); Cwirla *et al., Proc. Natl. Acad. Sci.,* **87:**6378-6382 (1990); Devlin *et al., Science,* **249:**404-406 (1990)] or a chemical library. In particular, based on the NMR structural analysis provided herein, compounds that comprise an "acetyl-amine-like" structure as depicted in Figure 12 are particularly good candidates. Examples of such "acetyl-lysine analogs" are included in [Figure 13] Table 15-1 to 15-33.

The following amended paragraph will replace the original paragraph starting on page 55, line 28, through line 4 on page 56:

According to the invention, the component or components of a therapeutic composition, *e.g.*, an agent of the invention that interferes with the bromodomain-acetyl-lysine binding complex such as the peptide having the amino acid sequence of SEQ ID NOs:4, 5, 6, 46, or 47, or an acetyl-lysine analog as defined by Figure 12 and exemplified in [Figure 13] Table 15-1 to 15-33, and a pharmaceutically acceptable carrier, may be introduced parenterally, transmucosally, *e.g.*, orally, nasally, or rectally, or transdermally. Preferably, administration is parenteral, *e.g.*, via intravenous injection, and also including, but is not limited to, intra-arteriole, intramuscular, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration.

IN THE CLAIMS:

The following claims have been amended to replace the original claims having the same claim number:

29. (Amended) A compound that is a small organic molecule identified by the method of Claim 28; wherein said compound is an analog of acetyl-lysine, but with the proviso that the compound is not included in [Figure 13] Table 15-1 to 15-33.

34. (Amended) A compound that is a small organic molecule identified by the method of Claim 33; wherein said compound is an analog of acetyl-lysine, but with the proviso that the compound is not included in [Figure 13] Table 15-1 to 15-33.

35. (Amended) An agent that can modulate the binding of P/CAF and Tat; wherein said agent is an analog of acetyl-lysine, but with the proviso that the agent is not included in [Figure 13] Table 15-1 to 15-33.

Structure	name	ID	Formula
	4-Acetamidoantipyrine	1	$C_{13}H_{15}N_3O_2$
	2-Acetamido-4-methylthiazole	166	$C_6H_8N_2OS$
	5-Acetamidothiazole	167	$C_5H_6N_2OS$
	2-Acetamido-5-benzylthio-1,3,4-thiadiazole	2	$C_{11}H_{11}N_3OS_2$
	4-Acetamido-2,2,6,6-tetramethylpiperidine	274	$C_{11}H_{22}N_2O$
	N4-Acetylcytosine	277	$C_6H_7N_3O_2$
	3-Acetamidocoumarin	3	$C_{11}H_9NO_3$
	Melatonin	31	$C_{13}H_{16}N_2O_2$

TABLE 15 - 1

Structure



name
N2,9-Diacetylguanine

ID 343 | Formula $C_9H_9N_5O_3$

Structure



name
N-Acetyl-5-hydroxytryptamine

ID 4 | Formula $C_{12}H_{14}N_2O_2$

Structure



name
Ethyl 2-(2-chloroacetamido)-4-thiazoleacetate

ID 415 | Formula $C_9H_{11}ClN_2O_3S$

Structure



name
2-Acetamidophenol

ID 500 | Formula $C_8H_9NO_2$

Structure



name
2-Acetylamino-malonic acid diethyl ester

ID 5100305 | Formula $C_9H_{15}NO_5$

Structure



name
N-(1-Methyl-2-phenyl-ethyl)-acetamide

ID 5100433 | Formula $C_{11}H_{15}NO$

Structure



name
2-(Acetylamino-methylene)-malonic acid diethyl ester

ID 5100929 | Formula $C_{10}H_{15}NO_5$

Structure



name
N-(2-(3,4-Dimethoxy-phenyl)-ethyl)-acetamide

ID 5102090 | Formula $C_{12}H_{17}NO_3$

TABLE 15 - 2



name
N-(2-(4-Methoxy-phenyl)-ethyl)-acetamide

ID 5102092 Formula $C_{11}H_{15}NO_2$



name
N-(1-Phenyl-1H-pyrazol-3-yl)-acetamide

ID 5102370 Formula $C_{11}H_{11}N_3O$



name
N-[4-(2-Cyano-ethylamino)-phenyl]-acetamide

ID 5102700 Formula $C_{11}H_{13}N_3O$



name
???

ID 5102701 Formula $C_{11}H_{12}N_4O_2$



name
N-[4-(2-Cyano-acetyl)-phenyl]-acetamide

ID 5102807 Formula $C_{11}H_{10}N_2O_2$



name
N-[4-(5-Amino-1H-pyrazol-3-yl)-phenyl]-acetamide

ID 5102808 Formula $C_{11}H_{12}N_4O$



name
N-(2-Bromo-4-methyl-phenyl)-acetamide

ID 5104354 Formula $C_9H_{10}BrNO$



name
N-(2-Ethoxy-phenyl)-acetamide

ID 5104364 Formula $C_{10}H_{13}NO_2$

TABLE 15 - 3



name
N-(3,5-Dihydroxy-phenyl)-acetamide

ID 5106727 | Formula $C_8H_9NO_3$



name
N-(4-Phenylazo-phenyl)-acetamide

ID 5106974 | Formula $C_{14}H_{13}N_3O$



name
N-(4-Benzyloxy-phenyl)-acetamide

ID 5107131 | Formula $C_{15}H_{15}NO_2$



name
N-(3-Cyano-4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-acetamide

ID 5107418 | Formula $C_{11}H_{12}N_2OS$



name
N-(3-Cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-acetamide

ID 5107423 | Formula $C_{10}H_{10}N_2OS$



name
N-(2-Methyl-benzothiazol-5-yl)-acetamide

ID 5107835 | Formula $C_{10}H_{10}N_2OS$



name
N-(1-Phenyl-ethyl)-acetamide

ID 5108520 | Formula $C_{10}H_{13}NO$



name
N-[1-(4-Nitro-benzoyl)-vinyl]-acetamide

ID 5110091 | Formula $C_{11}H_{10}N_2O_4$

TABLE 15 - 4



name: N-(4-Acetylamino-1-methyl-piperidin-4-yl)-acetamide

ID: 5118841 Formula: $C_{10}H_{19}N_3O_2$



name: N-Thiophen-2-yl-acetamide

ID: 5119019 Formula: C_6H_7NOS



name: 2-Fluoro-thiobenzoic acid S-(2-acetylamino-ethyl) ester

ID: 5119237 Formula: $C_{11}H_{12}FNO_2S$



name: 4-Fluoro-thiobenzoic acid S-(2-acetylamino-ethyl)-ester

ID: 5119238 Formula: $C_{11}H_{12}FNO_2S$



name: N-(2-Methylsulfanyl-ethyl)-acetamide

ID: 5119299 Formula: $C_5H_{11}NOS$



name: N-(2-Methanesulfinyl-ethyl)-acetamide

ID: 5119302 Formula: $C_5H_{11}NO_2S$



name: N-(2,2-Dimethyl-4-oxo-thietan-3-yl)-acetamide

ID: 5119316 Formula: $C_7H_{11}NO_2S$



name: N-(2-(2-Acetylamino-ethylsulfanyl)-ethyl)-acetamide

ID: 5119332 Formula: $C_8H_{16}N_2O_2S$

TABLE 15 - 5



name: N-(2-(2-Acetylamino-ethyldisulfanyl)-ethyl)-acetamide

ID 5119333 | Formula $C_8H_{16}N_2O_2S_2$



name: N-(5-Methoxy-quinolin-8-yl)-acetamide

ID 5121921 | Formula $C_{12}H_{12}N_2O_2$



name: 3-Acetylamino-benzoic acid

ID 5128194 | Formula $C_9H_9NO_3$



name: N-(5-Methyl-benzo[1,2,5]thiadiazol-4-yl)-acetamide

ID 5131057 | Formula $C_9H_9N_3OS$



name: (4-Acetylamino-phenyl)-ethyl-dimethyl-ammonium chloride

ID 5132286 | Formula $C_{12}H_{19}ClN_2O$



name: N-(4-Methanesulfonylamino-phenyl)-acetamide

ID 5133885 | Formula $C_9H_{12}N_2O_3S$



name: 4-Acetylamino-benzenesulfonate sodium

ID 5134865 | Formula $C_8H_8NNaO_4S$



name: (Z)-3-(4-Acetylamino-phenylcarbamoyl)-acrylic acid

ID 5135478 | Formula $C_{12}H_{12}N_2O_4$

TABLE 15 - 6

Structure	name	ID	Formula
	N-Naphthalen-2-yl-acetamide	5135520	$C_{12}H_{11}NO$
	N-(4-Acetylamino-phenyl)-acetamide	5135539	$C_{10}H_{12}N_2O_2$
	2-Acetylamino-5-guanidino-pentanoic acid	5137138	$C_8H_{16}N_4O_3$
	N-(2-Methoxy-phenyl)-acetamide	5137141	$C_9H_{11}NO_2$
	N-(5-Acetylamino-thiophen-2-yl)-acetamide	5137797	$C_8H_{10}N_2O_2S$
	4-Allyloxyacetanilide	514	$C_{11}H_{13}NO_2$
	N-Benzyl-2-phenoxy-acetamide	5140095	$C_{15}H_{15}NO_2$
	???	5144136	$C_9H_{13}N_3O_3S$

TABLE 15 - 7



name	ID	Formula
N-[Acetylamino-(4-fluoro-phenyl)-methyl]-acetamide	5145573	$C_{11}H_{13}FN_2O_2$



name	ID	Formula
N-(2-Methyl-quinolin-6-yl)-acetamide	5150046	$C_{12}H_{12}N_2O$



name	ID	Formula
N-(2'-Oxo-bicyclohexyl-1-yl)-acetamide	5151999	$C_{14}H_{23}NO_2$



name	ID	Formula
N-(4-Sulfamoyl-phenyl)-acetamide	5152132	$C_8H_{10}N_2O_3S$



name	ID	Formula
2-Acetylamino-4-methyl-thiazole-5-carboxylic acid ethyl ester	5144565	$C_9H_{12}N_2O_3S$



name	ID	Formula
N-(1-Hydroxy-2-oxo-2-phenyl-ethyl)-acetamide	5144583	$C_{10}H_{11}NO_3$



name	ID	Formula
5-Acetylamino-bicyclo[3.3.1]nonane-1-carboxylic acid	5145196	$C_{12}H_{19}NO_3$



name	ID	Formula
(Z)-2-Acetylamino-3-phenyl-acrylic acid	5145568	$C_{11}H_{11}NO_3$

TABLE 15 - 8

Structure



name
N-(4,5,6,7-Tetrahydro-benzo[b]thiophen-2-yl)-acetamide

ID 5156862 | Formula $C_{10}H_{13}NOS$

Structure



name
2-Chloro-N-(2-hydroxy-5-nitro-benzyl)-acetamide

ID 5157409 | Formula $C_9H_9ClN_2O_4$

Structure



name
N-(5-Hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-acetamide

ID 5160581 | Formula $C_{12}H_{13}N_3O_2$

Structure



name
4-Acetylamino-benzoic acid 3-methyl-butyl ester

ID 5161584 | Formula $C_{14}H_{19}NO_3$

Structure



name
N-(9H-Xanthen-9-yl)-acetamide

ID 5161930 | Formula $C_{15}H_{13}NO_2$

Structure



name
2-Acetylamino-3-(3H-imidazol-4-yl)-propionic acid

ID 5163605 | Formula $C_8H_{11}N_3O_3$

Structure



name
N-(2-Methyl-quinolin-4-yl)-acetamide

ID 5170552 | Formula $C_{12}H_{12}N_2O$

Structure



name
N-(8-Hydroxy-quinolin-2-yl)-acetamide

ID 5175095 | Formula $C_{11}H_{10}N_2O_2$

TABLE 15 - 9



name: N-(3-Diethylaminomethyl-4-hydroxy-phenyl)-acetamide

ID: 5175598 | Formula: $C_{13}H_{20}N_2O_2$



name: N-(5-Propionyl-thiophen-2-yl)-acetamide

ID: 5190716 | Formula: $C_9H_{11}NO_2S$



name: (E)-2-Acetylamino-3-(5-ethyl-thiophen-2-yl)-acrylic acid

ID: 5190720 | Formula: $C_{11}H_{13}NO_3S$



name: 10-Acetylamino-3-methyl-decanoic acid

ID: 5190763 | Formula: $C_{13}H_{25}NO_3$



name: 3-Acetylamino-nonanoic acid

ID: 5190776 | Formula: $C_{11}H_{21}NO_3$



name: N-(4-Phenoxy-phenyl)-acetamide

ID: 5191921 | Formula: $C_{14}H_{13}NO_2$



name: N-(5-Oxo-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-acetamide

ID: 5192544 | Formula: $C_{11}H_{11}N_3O_2$



name: N-[4-(2,5-Dimethyl-pyrrol-1-yl)-phenyl]-acetamide

ID: 5210476 | Formula: $C_{14}H_{16}N_2O$

TABLE 15 - 10



name: Furan-2-carboxylic acid (4-acetylamino-phenyl)-amide

ID 5210612 | Formula $C_{13}H_{12}N_2O_3$



name: N-(4-Hydroxymethanesulfonyl-phenyl)-acetamide

ID 5210745 | Formula $C_9H_{11}NO_4S$



name: N-(2,4-Dimethyl-6-nitro-phenyl)-acetamide

ID 5211945 | Formula $C_{10}H_{12}N_2O_3$



name: N-(4-Ethoxy-3-nitro-phenyl)-acetamide

ID 5211946 | Formula $C_{10}H_{12}N_2O_4$



name: N-(3-Chloro-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-acetamide

ID 5212521 | Formula $C_{12}H_8ClNO_3$



name: N-(1-{5-[(Z)-Hydroxyimino]-4-methyl-cyclohex-3-enyl}-1-methyl-ethyl)-acetamide

ID 5213911 | Formula $C_{12}H_{20}N_2O_2$



name: N-(4-{[1-(1H-Pyrrol-2-yl)-meth-(E)-ylidene]-amino}-phenyl)-acetamide

ID 5214576 | Formula $C_{13}H_{13}N_3O$



name: N-[2-(1-Methyl-cyclopropyl)-phenyl]-acetamide

ID 5216286 | Formula $C_{12}H_{15}NO$

TABLE 15 - 11



name: N-[6-(Acetylamino-methyl)-pyridin-2-ylmethyl]-acetamide

ID 5219860 | Formula $C_{11}H_{15}N_3O_2$



name: N-(4-Benzoyl-phenyl)-acetamide

ID 5226796 | Formula $C_{15}H_{13}NO_2$



name: N-(3-Dimethylamino-phenyl)-acetamide

ID 5228142 | Formula $C_{10}H_{14}N_2O$



name: 5-Acetylamino-isophthalic acid

ID 5233529 | Formula $C_{10}H_9NO_5$



name: N-(3-Acetyl-2-methyl-quinolin-4-yl)-acetamide

ID 5234425 | Formula $C_{14}H_{14}N_2O_2$



name: N-Tricyclo[4.3.1.1]undec-1-yl-acetamide

ID 5235037 | Formula $C_{13}H_{21}NO$



name: N-Isochroman-1-ylmethyl-acetamide

ID 5237699 | Formula $C_{12}H_{15}NO_2$



name: N-(3-Oxo-3-phenyl-propionyl)-acetamide

ID 5238359 | Formula $C_{11}H_{11}NO_3$

TABLE 15 - 12

Structure



name
N-[2-[(2-Hydroxy-benzoyl)-hydrazono]-propyl)-acetamide

ID 5238480 | Formula $C_{12}H_{15}N_3O_3$

Structure



name
N-(2-Trifluoromethyl-3H-benzoimidazol-5-yl)-acetamide

ID 5248854 | Formula $C_{10}H_8F_3N_3O$

Structure



name
N-[3-(2-Oxo-pyrrolidin-1-yl)-phenyl]-acetamide

ID 5249307 | Formula $C_{12}H_{14}N_2O_2$

Structure



name
5-Acetylamino-2-amino-benzenesulfonic acid

ID 5252844 | Formula $C_8H_{10}N_2O_4S$

Structure



name
N-(4-Morpholin-4-yl-phenyl)-acetamide

ID 5255410 | Formula $C_{12}H_{16}N_2O_2$

Structure



name
N-[4-(2-Hydroxy-ethanesulfonyl)-phenyl]-acetamide

ID 5255854 | Formula $C_{10}H_{13}NO_4S$

Structure



name
N-(3-Isopropylamino-2-nitroso-phenyl)-acetamide

ID 5256204 | Formula $C_{11}H_{15}N_3O_2$

Structure



name
N-Benzo[1,2,5]oxadiazol-4-yl-acetamide

ID 5256236 | Formula $C_8H_7N_3O_2$

Structure	name	ID	Formula
	(4-Acetylamino-phenyl)-carbamic acid methyl ester	5260987	$C_{10}H_{12}N_2O_3$
	N-(4-Acetylamino-phenyl)-succinamic acid	5266587	$C_{12}H_{14}N_2O_4$
	N-(2-Trifluoromethyl-1H-benzoimidazol-5-yl)-acetamide	5266605	$C_{10}H_8F_3N_3O$
	N-[4-(4-Methyl-piperazin-1-ylmethyl)-phenyl]-acetamide	5266853	$C_{14}H_{21}N_3O$
	(E)-But-2-enoic acid (4-acetylamino-phenyl)-amide	5268500	$C_{12}H_{14}N_2O_2$
	N-(4-Azepan-1-ylmethyl-phenyl)-acetamide	5269570	$C_{15}H_{22}N_2O$
	Furan-2-carboxylic acid (3-acetylamino-phenyl)-amide	5272899	$C_{13}H_{12}N_2O_3$
	N-[4-(2,2-Dicyano-vinyl)-phenyl]-acetamide	5274403	$C_{12}H_9N_3O$

TABLE 15 - 14



name: 4-Acetylamino-N,N-diethyl-benzamide

ID: 5279673 Formula: $C_{13}H_{18}N_2O_2$



name: N-(5-Chloro-2,4-dimethoxy-phenyl)-acetamide

ID: 5302797 Formula: $C_{10}H_{12}ClNO_3$



name: 5-Acetylamino-2-chloro-benzamide

ID: 5305312 Formula: $C_9H_9ClN_2O_2$



name: 3-Acetylamino-4-methoxy-benzamide

ID: 5306005 Formula: $C_{10}H_{12}N_2O_3$



name: N-(3-Cyano-4,5-dimethyl-thiophen-2-yl)-acetamide

ID: 5306046 Formula: $C_9H_{10}N_2OS$



name: 5-Acetylamino-2,4-dichloro-benzamide

ID: 5306181 Formula: $C_9H_8Cl_2N_2O_2$



name: 5-Acetylamino-isophthalamide

ID: 5308542 Formula: $C_{10}H_{11}N_3O_3$



name: N-(1,3-Dioxo-indan-2-yliden emethyl)-acetamide

ID: 5309532 Formula: $C_{12}H_9NO_3$

TABLE 15 - 15



name
N-(2-Methoxy-5-methyl-4-nitro-phenyl)-acetamide

ID 5310579 Formula $C_{10}H_{12}N_2O_4$



name
N-(4-Amino-2-methoxy-5-methyl-phenyl)-acetamide

ID 5311167 Formula $C_{10}H_{14}N_2O_2$



name
N-(4-Phenyl-furazan-3-yl)-acetamide

ID 5312808 Formula $C_{10}H_9N_3O_2$



name
N-(1-Acetyl-1H-[1,2,4]triazol-3-yl)-acetamide

ID 5313735 Formula $C_6H_8N_4O_2$



name
N-{4-{[1-(5-Methyl-furan-2-yl)-meth-(E)-ylidene]-amino}-phenyl)-acetamide

ID 5313754 Formula $C_{14}H_{14}N_2O_2$



name
N-(8-Methoxy-2,3-dimethyl-quinoxalin-5-yl)-acetamide

ID 5316088 Formula $C_{13}H_{15}N_3O_2$



name
N-[5-(4-Methoxy-phenyl)-[1,3,4]thiadiazol-2-yl]-acetamide

ID 5316146 Formula $C_{11}H_{11}N_3O_2S$



name
(2-Acetylamino-phenyl)-oxo-acetic acid ethyl ester

ID 5323911 Formula $C_{12}H_{13}NO_4$

TABLE 15 - 16



name
N-(6-Methoxy-2-methyl-benzothiazol-7-yl)-acetamide

ID 5325303 Formula $C_{11}H_{12}N_2O_2S$



name
N-(4-Chloro-2,5-dimethoxy-phenyl)-acetamide

ID 5331993 Formula $C_{10}H_{12}ClNO_3$



name
4-Acetylamino-N-isopropyl-benzamide

ID 5334418 Formula $C_{12}H_{16}N_2O_2$



name
N-(4-Oxo-adamantan-1-yl)-acetamide

ID 5346256 Formula $C_{12}H_{17}NO_2$



name
N-(7-Methylene-bicyclo[3.3.1]non-2-en-3-yl)-acetamide

ID 5347722 Formula $C_{12}H_{17}NO$



name
N-(3-Hydroxy-adamantan-1-yl)-acetamide

ID 5347923 Formula $C_{12}H_{19}NO_2$



name
N-Hydrazinocarbonylmethyl-2-phenoxy-acetamide

ID 5352012 Formula $C_{10}H_{13}N_3O_3$



name
N-(3-Hydroxy-5,7-dimethyl-adamantan-1-yl)-acetamide

ID 5352666 Formula $C_{14}H_{23}NO_2$

TABLE 15 - 17

Structure



name
N-[2-Acetylamino-1-methyl-eth-(E)-ylidene]-hydrazinecarboxylic acid ethyl ester

ID	Formula
5353737	$C_8H_{15}N_3O_3$

Structure



name
N-(6-Methyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-acetamide

ID	Formula
5373714	$C_{15}H_{18}N_2O$

Structure



name
N-(4-Indolizin-2-yl-phenyl)-acetamide

ID	Formula
5380715	$C_{16}H_{14}N_2O$

Structure



name
N-Allyl-2-(4-chloro-phenoxy)-acetamide

ID	Formula
5403642	$C_{11}H_{12}ClNO_2$

Structure



name
N-[2-(2-Fluoro-phenoxy)-ethyl]-acetamide

ID	Formula
5404444	$C_{10}H_{12}FNO_2$

Structure



name
N-(4-{[(2-Hydroxy-ethyl)-propyl-amino]-methyl}-phenyl)-acetamide

ID	Formula
5423275	$C_{14}H_{22}N_2O_2$

Structure



name
N-(4-Piperidin-1-ylmethyl-phenyl)-acetamide

ID	Formula
5425039	$C_{14}H_{20}N_2O$

Structure



name
N-(4-Morpholin-4-ylmethyl-phenyl)-acetamide

ID	Formula
5426608	$C_{13}H_{18}N_2O_2$

TABLE 15 - 18



name	ID	Formula
N-(4-Hydroxy-2-methyl-quinolin-6-yl)-acetamide	5470439	$C_{12}H_{12}N_2O_2$



name	ID	Formula
N-(6-Acetylamino-1-oxy-pyridin-2-yl)-acetamide	5474173	$C_9H_{11}N_3O_3$



name	ID	Formula
4-Fluoroacetanilide	548	C_8H_8FNO



name	ID	Formula
N-(4-tert-Butyl-2-nitro-phenyl)-acetamide	5485259	$C_{12}H_{16}N_2O_3$



name	ID	Formula
N-{4-{[1-Pyridin-4-yl-meth-(E)-ylidene]-amino}-phenyl}-acetamide	5509419	$C_{14}H_{13}N_3O$



name	ID	Formula
N-(1H-Tetrazol-5-yl)-acetamide	5510963	$C_3H_5N_5O$



name	ID	Formula
Pyridin-3-yl-carbamic acid 2-acetylamino-ethyl ester	5522408	$C_{10}H_{13}N_3O_3$



name	ID	Formula
N-Allyl-2-phenoxy-acetamide	5523973	$C_{11}H_{13}NO_2$

TABLE 15 - 19

Structure	name	ID	Formula
	N-(3,6-Dihydro-benzo[1,2-1 d;3,4-d']bistriazol-4-yl)-acet amide	5529796	$C_8H_7N_7O$
	N-(2-Methoxy-ethyl)-2-phen oxy-acetamide	5531808	$C_{11}H_{15}NO_3$
	N-(3-Methoxy-propyl)-2-phe noxy-acetamide	5544954	$C_{12}H_{17}NO_3$
	N-(3-Dimethylamino-propyl) -2-phenoxy-acetamide	5548376	$C_{13}H_{20}N_2O_2$
	N-(5-Phenyl-[1,3,4]oxadiazo l-2-yl)-acetamide	5549905	$C_{10}H_9N_3O_2$
	N-(1-Butyl-1H-benzoimidaz ol-2-yl)-acetamide	5553131	$C_{13}H_{17}N_3O$
	2-(4-Chloro-phenoxy)-N-(2-methoxy-ethyl)-acetamide	5553166	$C_{11}H_{14}ClNO_3$
	N-(1-Propyl-1H-benzoimida zol-2-yl)-acetamide	5553756	$C_{12}H_{15}N_3O$

TABLE 15 - 20



name
2-Acetylamino-3-benzo[1,3]dioxol-5-yl-acrylic acid

ID 5558887 Formula $C_{12}H_{11}NO_5$



name
Pyridin-4-yl-carbamic acid 2-acetylamino-ethyl ester

ID 5561171 Formula $C_{10}H_{13}N_3O_3$



name
2-Phenoxy-N-(tetrahydro-furan-2-ylmethyl)-acetamide

ID 5563979 Formula $C_{13}H_{17}NO_3$



name
N-[2-(1H-Tetrazol-5-yl)-phenyl]-acetamide

ID 5583145 Formula $C_9H_9N_5O$



name
N-[1-(3,4-Dichloro-phenyl)-ethyl]-acetamide

ID 5583493 Formula $C_{10}H_{11}Cl_2NO$



name
N-[1-(4-Bromo-phenyl)-ethyl]-acetamide

ID 5587422 Formula $C_{10}H_{12}BrNO$



name
N-(4-Diethylamino-phenyl)-acetamide

ID 5624080 Formula $C_{12}H_{18}N_2O$



name
N-(5-Hydroxy-7-methoxy-benzo[1,2,5]oxadiazol-4-yl)-acetamide

ID 5626437 Formula $C_9H_9N_3O_4$

TABLE 15 - 21



name
5-(N'-Acetyl-guanidino)-2-amino-pentanoic acid

ID 5626440 Formula $C_8H_{16}N_4O_3$



name
N-(5-Phenoxymethyl-[1,3,4]thiadiazol-2-yl)-acetamide

ID 5633778 Formula $C_{11}H_{11}N_3O_2S$



name
N-[4-(3-Allyl-thioureido)-phenyl]-acetamide

ID 5634206 Formula $C_{12}H_{15}N_3OS$



name
N-(6-Ethyl-7-hydroxy-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-acetamide

ID 5652409 Formula $C_{10}H_{13}N_5O_2$



name
N-(1-tert-Butyl-1H-benzoimidazol-5-yl)-acetamide

ID 5655930 Formula $C_{13}H_{17}N_3O$



name
N-(7-Hydroxy-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-acetamide

ID 5656027 Formula $C_8H_9N_5O_2$



name
N-(5-p-Tolyl-4H-[1,2,4]triazol-3-yl)-acetamide

ID 5656455 Formula $C_{11}H_{12}N_4O$



name
N-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-acetamide

ID 5660405 Formula $C_{11}H_{13}N_3O$



Structure

name
N-(7-Oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl)-acetamide

ID 5674030 | Formula $C_9H_{10}N_2O_2S$



Structure

name
(Z)-2-Acetylamino-3-(4-ethoxy-phenyl)-acrylic acid

ID 5685865 | Formula $C_{13}H_{15}NO_4$



Structure

name
(E)-2-Acetylamino-3-(3-nitro-phenyl)-acrylic acid

ID 5687268 | Formula $C_{11}H_{10}N_2O_5$



Structure

name
(E)-2-Acetylamino-3-(3-nitro-phenyl)-acrylic acid

ID 5688836 | Formula $C_{12}H_{13}NO_4$



Structure

name
N-[4-((E)-3-Chloro-but-2-enyloxy)-phenyl]-acetamide

ID 5689801 | Formula $C_{12}H_{14}ClNO_2$



Structure

name
N-(2-Dimethylamino-ethyl)-2-(3,5-dimethyl-phenoxy)-acetamide

ID 5690899 | Formula $C_{14}H_{22}N_2O_2$



Structure

name
Acetic acid (3R,4S)-4-acetylamino-tetrahydro-thiophen-3-yl ester

ID 5728428 | Formula $C_8H_{13}NO_3S$



Structure

name
4-Acetylamino-N-(2-methoxy-ethyl)-benzamide

ID 5739448 | Formula $C_{12}H_{16}N_2O_3$

Structure



name
4-Acetylamino-N-(3-methoxy-propyl)-benzamide

ID 5739629 | Formula $C_{13}H_{18}N_2O_3$

Structure



name
(4-Acetylamino-benzoylamino)-acetic acid methyl ester

ID 5740840 | Formula $C_{12}H_{14}N_2O_4$

Structure



name
2-(2-Chloro-phenoxy)-N-(2-methoxy-ethyl)-acetamide

ID 5798772 | Formula $C_{11}H_{14}ClNO_3$

Structure



name
2-(4-Chloro-2-methyl-phenoxy)-N-(2-hydroxy-ethyl)-acetamide

ID 5809836 | Formula $C_{11}H_{14}ClNO_3$

Structure



name
N-(5-Acetyl-2,6-dimethyl-pyrimidin-4-yl)-acetamide

ID 5810733 | Formula $C_{10}H_{13}N_3O_2$

Structure



name
N-(2-Hydroxy-ethyl)-2-(naphthalen-1-yloxy)-acetamide

ID 5811720 | Formula $C_{14}H_{15}NO_3$

Structure



name
N-[Acetylamino-(2-chloro-phenyl)-methyl]-acetamide

ID 5824734 | Formula $C_{11}H_{13}ClN_2O_2$

Structure



name
N-{1-[6,6-Dimethyl-3-oxo-bicyclo[3.1.0]hex-(2Z)-ylidene]-ethyl}-acetamide

ID 5827999 | Formula $C_{12}H_{17}NO_2$

Structure



name
N-(Acetylamino-phenyl-methyl)-acetamide

ID 5828027 Formula $C_{11}H_{14}N_2O_2$

Structure



name
N-[4-(2-Amino-thiazol-4-yl)-phenyl]-acetamide

ID 5835173 Formula $C_{11}H_{11}N_3OS$

Structure



name
4-Acetylamino-benzoic acid butyl ester

ID 5840961 Formula $C_{13}H_{17}NO_3$

Structure



name
N-(4-Propyl-bicyclo[2.2.2]oct-1-yl)-acetamide

ID 5850382 Formula $C_{13}H_{23}NO$

Structure



name
N-[5-(4-Fluoro-benzyl)-thiazol-2-yl]-acetamide

ID 5851471 Formula $C_{12}H_{11}FN_2OS$

Structure



name
N-(5-Benzyl-thiazol-2-yl)-acetamide

ID 5853200 Formula $C_{12}H_{12}N_2OS$

Structure



name
N-Allyl-2-(2,4-dimethyl-phenoxy)-acetamide

ID 5854702 Formula $C_{13}H_{17}NO_2$

Structure



name
N-(4-Thiophen-2-yl-thiazol-2-yl)-acetamide

ID 5879151 Formula $C_9H_8N_2OS_2$

TABLE 15 - 25



name: 3-Acetylamino-5-amino-4-chloro-benzoic acid

ID: 5926651 Formula: $C_9H_9ClN_2O_3$



name: N-(2-Ethoxy-4-nitro-phenyl)-acetamide

ID: 5940353 Formula: $C_{10}H_{12}N_2O_4$



name: N-(5-Ethoxymethyl-2-methyl-pyrimidin-4-yl)-acetamide

ID: 5968775 Formula: $C_{10}H_{15}N_3O_2$



name: N-[5-(4-Chloro-phenyl)-2H-pyrazol-3-yl]-acetamide

ID: 5993802 Formula: $C_{11}H_{10}ClN_3O$



name: N-(6-Methyl-2-oxo-2H-chromen-3-yl)-acetamide

ID: 6037500 Formula: $C_{12}H_{11}NO_3$



name: N-(8-Nitro-2-oxo-2H-chromen-3-yl)-acetamide

ID: 6037721 Formula: $C_{11}H_8N_2O_5$



name: N-(4-Furan-2-yl-phenyl)-acetamide

ID: 6039007 Formula: $C_{12}H_{11}NO_2$



name: N-(8-Methoxy-2-oxo-2H-chromen-3-yl)-acetamide

ID: 6041557 Formula: $C_{12}H_{11}NO_4$

TABLE 15 - 26



N-(8-Allyl-2-oxo-2H-chromen-3-yl)-acetamide

ID 6041610 — Formula $C_{14}H_{13}NO_3$



N-(6-Chloro-2-oxo-2H-chromen-3-yl)-acetamide

ID 6041848 — Formula $C_{11}H_8ClNO_3$



N-(2-{[2-Oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-amino}-ethyl)-acetamide

ID 6043527 — Formula $C_{13}H_{15}N_3O_2$



N-Allyl-2-(4-chloro-3-methyl-phenoxy)-acetamide

ID 6045963 — Formula $C_{12}H_{14}ClNO_2$



N-Allyl-2-(4-isopropyl-phenoxy)-acetamide

ID 6047729 — Formula $C_{14}H_{19}NO_2$



N-Allyl-2-(4-propyl-phenoxy)-acetamide

ID 6048040 — Formula $C_{14}H_{19}NO_2$



N-(6-Methoxy-benzothiazol-2-yl)-acetamide

ID 6048159 — Formula $C_{10}H_{10}N_2O_2S$



N-(8-Oxo-6,7,8,9-tetrahydro-5H-carbazol-3-yl)-acetamide

ID 6048242 — Formula $C_{14}H_{14}N_2O_2$

TABLE 15 - 27

Structure	name	ID	Formula
	N-[1-(2-Dimethylamino-ethyl)-1H-benzoimidazol-2-yl]-acetamide	6048903	$C_{13}H_{18}N_4O$
	4-(2-Acetylamino-ethoxy)-benzoic acid	6050206	$C_{11}H_{13}NO_4$
	N-(2-Methoxy-ethyl)-2-o-tolyloxy-acetamide	6080836	$C_{12}H_{17}NO_3$
	N-(Tetrahydro-furan-2-ylmethyl)-2-o-tolyloxy-acetamide	6081107	$C_{14}H_{19}NO_3$
	N-Allyl-2-o-tolyloxy-acetamide	6081805	$C_{12}H_{15}NO_2$
	N-Isobutyl-2-p-tolyloxy-acetamide	6082132	$C_{13}H_{19}NO_2$
	N-(3-Methoxy-propyl)-2-o-tolyloxy-acetamide	6084617	$C_{13}H_{19}NO_3$
	N-Allyl-2-m-tolyloxy-acetamide	6085276	$C_{12}H_{15}NO_2$

TABLE 15 - 28

Structure



name
N-(3-Dimethylamino-propyl) -2-m-tolyloxy-acetamide

ID 6085715 | Formula $C_{14}H_{22}N_2O_2$

Structure



name
N-(3-Dimethylamino-propyl) -2-o-tolyloxy-acetamide

ID 6088320 | Formula $C_{14}H_{22}N_2O_2$

Structure



name
N-(2-Methoxy-ethyl)-2-m-tol yloxy-acetamide

ID 6089795 | Formula $C_{12}H_{17}NO_3$

Structure



name
N-(4-Acetylamino-phenyl)-3 -oxo-butyramide

ID 6091016 | Formula $C_{12}H_{14}N_2O_3$

Structure



name
N-(3-Methoxy-propyl)-2-m-t olyloxy-acetamide

ID 6091675 | Formula $C_{13}H_{19}NO_3$

Structure



name
N-(3-Methoxy-propyl)-2-p-to lyloxy-acetamide

ID 6093568 | Formula $C_{13}H_{19}NO_3$

Structure



name
N-Furan-2-ylmethyl-2-m-tol yloxy-acetamide

ID 6094336 | Formula $C_{14}H_{15}NO_3$

Structure



name
N-Isobutyl-2-m-tolyloxy-ace tamide

ID 6095380 | Formula $C_{13}H_{19}NO_2$

Structure	Structure	Structure	Structure
			
name: 2-Phenoxy-N-pyridin-2-ylmethyl-acetamide	name: N-[3-(4-Nitro-phenylamino)-propyl]-acetamide	name: Nw-Acetylhistamine	name: 2-(2,4-Dimethyl-phenoxy)-N-(2-hydroxy-ethyl)-acetamide
ID: 6096864 Formula: $C_{14}H_{14}N_2O_2$	ID: 6098516 Formula: $C_{11}H_{15}N_3O_3$	ID: 61 Formula: $C_7H_{11}N_3O$	ID: 6120704 Formula: $C_{12}H_{17}NO_3$
Structure	Structure	Structure	Structure
			
name: N-(4-Acetylamino-phenyl)-oxalamic acid ethyl ester	name: N-[4-(2,5-Dimethyl-phenyl)-thiazol-2-yl]-acetamide	name: N-[4-(3,4-Dimethyl-phenyl)-thiazol-2-yl]-acetamide	name: N-Allyl-2-(naphthalen-2-yloxy)-acetamide
ID: 6127010 Formula: $C_{12}H_{14}N_2O_4$	ID: 6131496 Formula: $C_{13}H_{14}N_2OS$	ID: 6131723 Formula: $C_{13}H_{14}N_2OS$	ID: 6139453 Formula: $C_{15}H_{15}NO_2$

TABLE 15 - 30



name
N-(4-Methyl-5-p-tolyl-2H-pyrazol-3-yl)-acetamide

ID 6140272 | Formula $C_{13}H_{15}N_3O$



name
N-[5-(4-Fluoro-phenyl)-2H-pyrazol-3-yl]-acetamide

ID 6143917 | Formula $C_{11}H_{10}FN_3O$



name
N-(5-p-Tolyl-2H-pyrazol-3-yl)-acetamide

ID 6144889 | Formula $C_{12}H_{13}N_3O$



name
N-(4,7-Dimethyl-2-oxo-2H-chromen-6-yl)-acetamide

ID 6153309 | Formula $C_{13}H_{13}NO_3$



name
N-(5-m-Tolyl-2H-pyrazol-3-yl)-acetamide

ID 6160287 | Formula $C_{12}H_{13}N_3O$



name
N-[5-(2-Chloro-phenyl)-2H-pyrazol-3-yl]-acetamide

ID 6163418 | Formula $C_{11}H_{10}ClN_3O$



name
3-(2-Phenoxy-acetylamino)-propionic acid

ID 6239633 | Formula $C_{11}H_{13}NO_4$



name
4-(2-Phenoxy-acetylamino)-butyric acid

ID 6240756 | Formula $C_{12}H_{15}NO_4$



name
N-[Acetylamino-(4-dimethyl amino-phenyl)-methyl]-acet amide

ID 6240978 | Formula $C_{13}H_{19}N_3O_2$



name
N-(1-tert-Butyl-3,4-dimethyl -5-oxo-2,5-dihydro-1H-pyrr ol-2-yl)-acetamide

ID 6326390 | Formula $C_{12}H_{20}N_2O_2$



name
N-(2-Trifluoromethylsulfany l-phenyl)-acetamide

ID 6368433 | Formula $C_9H_8F_3NOS$



name
N-(4-Trifluoromethylsulfany l-phenyl)-acetamide

ID 6368862 | Formula $C_9H_8F_3NOS$



name
N-(5-Methyl-4-p-tolyl-thiazol -2-yl)-acetamide

ID 6404355 | Formula $C_{13}H_{14}N_2OS$



name
3-Acetamidoacetophenone

ID 659 | Formula $C_{10}H_{11}NO_2$



name
3-Acetamidophenol

ID 660 | Formula $C_8H_9NO_2$



name
4-tert-Butylacetanilide

ID 700 | Formula $C_{12}H_{17}NO$

TABLE 15 - 32



name	
2-(2-Chloroacetamido)-4-thiazoleacetic acid	
ID	Formula
8	$C_7H_7ClN_2O_3S$

TABLE 15 - 33